Solid Biosciences (SLDB) Cash from Operations (2017 - 2026)
Solid Biosciences (SLDB) posted Cash from Operations of 47230000.0 for Q1 2026, up 11.81% sequentially from 53555000.0 in Q4 2025, and down 48.29% YoY from 91334274.44 in Q1 2025.
Powered by 
Analysis
Solid Biosciences (SLDB) Cash from Operations (2017 - 2026) Analysis & Trends
Solid Biosciences has reported Cash from Operations for 10 years, with the latest figure at 47230000.0 in Q1 2026.
- Quarterly Cash from Operations fell 48.29% year-over-year to 47230000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 171669000.0 (down 60.93% YoY) and the FY2025 annual result came in at 156289000.0, down 56.27% from the prior year.
- Cash from Operations grew to 47230000.0 in Q1 2026 per SLDB's latest filing, from 53555000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 15878000.0 in Q2 2022 and troughed at 53555000.0 in Q4 2025.
- A 5-year average of 29158117.65 and a median of 27465000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations jumped 39.61% in 2023, then plunged 80.65% in 2025.
- Over 5 years, Cash from Operations stood at 34480000.0 in 2022, then surged by 39.61% to 20823000.0 in 2023, then tumbled by 42.37% to 29645000.0 in 2024, then plunged by 80.65% to 53555000.0 in 2025, then grew by 11.81% to 47230000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 47230000.0, 53555000.0, and 33472000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | -52.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -52.59 Mn |
| Mar 31, 2026 | -47.23 Mn |
| Dec 31, 2025 | -53.57 Mn |
| Sep 30, 2025 | -33.47 Mn |
| Jun 30, 2025 | -37.41 Mn |
| Mar 31, 2025 | -31.85 Mn |
| Dec 31, 2024 | -29.65 Mn |
| Sep 30, 2024 | -23.71 Mn |
| Jun 30, 2024 | -21.47 Mn |
| Mar 31, 2024 | -25.19 Mn |
| Dec 31, 2023 | -20.82 Mn |
| Sep 30, 2023 | -17.90 Mn |
| Jun 30, 2023 | -27.47 Mn |
| Mar 31, 2023 | -28.00 Mn |
| Dec 31, 2022 | -34.48 Mn |
| Sep 30, 2022 | -20.43 Mn |
| Jun 30, 2022 | -15.88 Mn |
| Mar 31, 2022 | -27.19 Mn |
| Dec 31, 2021 | -20.87 Mn |
| Sep 30, 2021 | -18.42 Mn |